12 February 2021, 17:00 CET
Dr Takis Athanasopoulos is head of vector & transgene as part of the Cell & Gene Therapy Research & Discovery platform at GSK, Stevenage, UK. Before joining GSK, Takis was a Lecturer in Molecular Biotechnology at the University of Wolverhampton (September 2011-2016) and Academic Visitor/Research Consultant for the Gene Therapy Group at Royal Holloway University of London. Before joining the Faculty of Science and Engineering at UoW, Takis was a member of the Collaboration for AIDS Vaccine Discovery (CAVD) (www.cavd.org) - an international network of scientists and experts dedicated to designing a variety of novel HIV vaccine candidates and advancing the most promising ones to clinical trials.
Takis has previously worked as a research scientist in the School of Biological Sciences at Royal Holloway, University of London (RHUL) (www.rhul.ac.uk). He has also worked on collaborative projects with scientists and clinicians at the Royal Free Hospital (UCL) and Imperial College London (ICL). Previously he has been funded by the State Scholarship Foundation SF/IKY (Greece), Muscular Dystrophy Campaign (UK), the Collaboration for AIDS Vaccine Discovery (CAVD) (www.cavd.org) and the Bill & Melinda Gates Foundation (BMGF).
He has developed critical expertise on various vector systems’ technologies through conducting, collaborating and managing a number of diverse research projects. He holds a BSc in Biochemistry from University of Patras, Greece, and a PhD in Biomedical Sciences from the University of London.
Areas of Research Interests: Gene Therapy, Virology, Genetic Vaccines & Research Consulting.